Delivery Order SPE2DB24D2105-SPE2DB25FAQBD
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of REPATHA 140 mg/ml SureClick auto-injectors, valued at $1,041.42. This is a firm fixed-price delivery order with an ultimate completion date of August 6, 2025, and represents a non-competitive set-aside award. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $6,614.91 to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of July 29, 2025. This non-set-aside, firm fixed price contract was competitively awarded on July 28, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency has awarded a delivery order valued at $4,865.38 to AmerisourceBergen Drug Corp for the supply of REPATHA 140 mg/mL SureClick auto-injectors. This competitively awarded, firm fixed-price delivery order was issued on July 18, 2025, with an ultimate completion date of July 21, 2025. The place of performance is AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. This delivery order represents a child contract action under AmerisourceBergen's...
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation. The order is for REPATHA 140 MG/ML SYRINGEML, a pharmaceutical product. The contract has a ceiling value of $2,019.60 and a period of performance through April 4, 2024. AmerisourceBergen Drug Corp is the prime contractor, and there are no set-aside designations. This delivery order is issued under a larger indefinite delivery...
- The Defense Logistics Agency awarded a delivery order valued at $12,889.99 to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with an ultimate completion date of August 5, 2025. This non-set-aside, firm fixed-price delivery order represents a competitive award to the pharmaceutical distributor and represents a continuation of the company's ongoing supply relationship with DLA. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $6,293.41 to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injector pharmaceutical product. The contract, executed on August 7, 2025, with completion targeted for August 8, 2025, utilized firm fixed-price pricing with no set-aside designation, indicating competitive award. This delivery order represents a child contract under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with a ceiling value of $1,041.42. This competitively awarded, firm fixed-price delivery order was issued on July 31, 2025, with an ultimate completion date of August 1, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. REPATHA is a prescription medication used to treat high cholesterol and reduce...
- The Defense Logistics Agency awarded a delivery order valued at $1,041.42 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/mL SureClick auto-injectors. This competitively awarded, firm fixed-price delivery order was issued on July 29, 2025, with an ultimate completion date of July 30, 2025, and will be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $1,077.36 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injector pharmaceutical products on August 7, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating competitive award conditions. Performance will be completed by August 8, 2025, with work performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order represents a child...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,135.32 firm fixed-price delivery order is for the supply of REPATHA 140 MG/ML SYRINGEML, a specialty medication. The contract has an ultimate completion date of March 10, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
- SPE2DB24D2105Indefinite Delivery Contract
- SPE2DB24D2105-SPE2DB25FAQBDDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml syringes valued at $1,822.81 under a firm fixed price contract type. The award was made on August 11, 2025, with an ultimate completion date of August 12, 2025, and does not utilize a set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order at its corporate office location in Conshohocken, PA 19428. This delivery order represents a child contract action under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. REPATHA, a cholesterol-lowering injection used in cardiovascular disease management, falls within the specialized pharmaceutical products covered under this extensive contract vehicle that supports military healthcare systems, the Defense Health Agency, U.S. Coast Guard, and other government healthcare organizations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 8/11/25 |